Research programme - CAR cell therapies - Outpace Bio
Alternative Names: CAR-T cell therapies - Outpace BioLatest Information Update: 14 Jun 2024
Price :
$50 *
At a glance
- Originator Outpace Bio
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Apr 2024 Interim pharmacodynamics data from a preclinical studies in solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 25 May 2023 Pharmacodynamics data from preclinical studies in Solid tumours released by Outpace Bio
- 18 May 2023 Preclinical trials in Solid tumours in USA (Parenteral) before May 2023